Cansortium Reports Third Quarter 2021 Financial Results
Q3 Revenue up 9% YoY to
Management to Host Conference Call Today at
"We executed on several key initiatives during the quarter, including the opening of a new dispensary in
"During the quarter, there was a well-publicized merger between two MSOs in
Beasley continued: "Pricing volatility in
Q3 2021 Financial Highlights (vs. Q3 2020)
- Revenue increased 9% to
$15.6 million compared to$14.3 million . Florida revenue increased 4.3% to$13.1 million compared to$12.6 million .- Adjusted gross profit1 increased to
$9.8 million or 62.7% of revenue, compared to$9.5 million or 66.6% of revenue. - Adjusted EBITDA increased 34% to
$4.9 million or 31.4% of revenue, compared to$3.6 million or 25.5% of revenue.
Recent Operational Highlights
- In August, the Company opened its 2nd store in
Pennsylvania inMechanicsburg . - In September, the Company opened its 27th store in
Florida inFruitland Park , which is the city's first medical marijuana dispensary. - Received approval from the
Florida Department of Health to commence operations at several new bays at itsSweetwater, FL cultivation facility. Cansortium appointed a new auditor,Baker Tilly US, LLP , in preparation for reporting financial results in accordance withU.S. GAAP in 2022.
2021 Outlook
The Company is revising its 2021 outlook for revenue and now expects it to range between
The Company's unaudited consolidated financial statements and accompanying notes, along with the Management Discussion and Analysis (MD&A), will be available under the Company's profile on SEDAR at www.sedar.com and are also accessible through the Investor Relations section of the Company's website at www.getfluent.com.
______________________________ |
1 Adjusted gross profit is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. The Company calculates adjusted gross profit from gross profit plus (minus) the changes in fair value of biological assets, as presented in the consolidated statement of operations. |
Conference Call
The Company will host a conference call and live audio webcast today at
Toll-free dial-in number: (800) 319-4610
International dial-in number: (604) 638-5340
Conference ID: 10017358
Link:
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Elevate IR at (949) 200-4603.
The conference call will also be available for replay via the News & Events section of the Company's investor relations website at https://investors.getfluent.com/.
About
Forward-Looking Information
Certain information in this news release may constitute forward-looking information. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In addition, any statements that refer to expectations, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events.
Forward-looking information is necessarily based on many opinions, assumptions, and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to the factors described in the public documents of the Company available at www.sedar.com. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. There can be no assurance that such estimates and assumptions will prove to be correct. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
For further information: www.getfluent.com
Company Contact
(305) 900-6266
www.getfluent.com
Investor Relations Contact
Elevate IR
(949) 200-4603
investors@cansortium.com
Media Contact
Grasslands: A Journalism-Minded Agency
julie@mygrasslands.com
(978) 502-7705
|
||||
CONSOLIDATED STATEMENTS OF FINANCIAL POSITION |
||||
As of |
||||
(USD '000) |
||||
|
|
|||
Assets |
||||
Current assets |
||||
Cash and cash equivalents |
$ |
13,808 |
$ |
3,392 |
Accounts receivable |
301 |
148 |
||
Inventory, net |
9,975 |
5,006 |
||
Biological assets |
3,108 |
1,914 |
||
Prepaid income taxes |
628 |
- |
||
Note receivable |
3,986 |
3,859 |
||
Prepaid expenses and other current assets |
1,657 |
1,365 |
||
Total current assets |
33,463 |
15,684 |
||
Investment held for sale |
200 |
200 |
||
Property and equipment, net |
30,369 |
19,517 |
||
Intangible assets, net |
96,205 |
97,035 |
||
Right-of-use assets |
19,290 |
19,094 |
||
Deposit |
2,727 |
1,050 |
||
|
1,526 |
1,526 |
||
Other assets |
528 |
425 |
||
Total assets |
$ |
184,308 |
$ |
154,531 |
Liabilities |
||||
Current liabilities |
||||
Accounts payable |
4,685 |
4,808 |
||
Accrued liabilities |
7,092 |
7,614 |
||
Income taxes payable |
- |
8,925 |
||
Derivative liabilities |
- |
7,412 |
||
Current portion of notes payable |
620 |
38,583 |
||
Lease obligations |
2,375 |
1,894 |
||
Total current liabilities |
14,772 |
69,236 |
||
- |
||||
Notes payable |
54,693 |
13,182 |
||
Lease obligations, net of current portion |
21,157 |
20,811 |
||
Deferred income taxes |
21,547 |
23,471 |
||
Total liabilities |
112,169 |
126,700 |
||
Shareholders' equity |
||||
Share capital |
193,020 |
137,835 |
||
Share-based compensation reserve |
6,164 |
4,675 |
||
Equity conversion feature |
4,933 |
11,044 |
||
Warrants |
29,797 |
13,265 |
||
Accumulated deficit |
(161,363) |
(138,609) |
||
Accumulated other comprehensive loss |
(412) |
(379) |
||
Total shareholders' equity |
72,139 |
27,831 |
||
Total liabilities and shareholders' equity |
$ |
184,308 |
$ |
154,531 |
|
||||||||||
STATEMENT OF OPERATIONS |
||||||||||
FOR THE THREE AND NINE MONTHS ENDED |
||||||||||
(USD '000) |
||||||||||
For the three months |
For the nine months |
|||||||||
2021 |
2020 |
2021 |
2020 |
|||||||
Revenue, net of discounts |
$ |
15,568 |
$ |
14,313 |
$ |
47,153 |
$ |
37,718 |
||
Cost of goods sold |
5,805 |
4,784 |
$ |
16,956 |
13,011 |
|||||
Gross profit before fair value adjustments |
9,763 |
9,529 |
30,197 |
24,707 |
||||||
Realized fair value of increments on inventory sold |
(5,113) |
(6,051) |
(14,433) |
(18,566) |
||||||
Unrealized change in fair value of biological assets |
6,113 |
4,263 |
11,768 |
23,945 |
||||||
Gross profit |
10,763 |
7,741 |
27,532 |
30,086 |
||||||
Expenses |
||||||||||
General and administrative |
2,084 |
2,861 |
8,241 |
9,064 |
||||||
Share-based compensation |
731 |
1,689 |
4,248 |
4,938 |
||||||
Sales and marketing |
4,033 |
3,561 |
11,094 |
10,162 |
||||||
Depreciation and amortization |
1,649 |
1,561 |
4,727 |
4,635 |
||||||
Total expenses |
8,497 |
9,672 |
28,310 |
28,799 |
||||||
Income (Loss) from operations |
2,266 |
(1,931) |
(778) |
1,287 |
||||||
Other expense (income) |
||||||||||
Interest expense, net |
3,383 |
3,892 |
11,233 |
11,448 |
||||||
Change in fair market value of derivative liability |
- |
673 |
(1,551) |
1,680 |
||||||
(Gain)/Loss on debt settlement |
(10,794) |
- |
(42) |
- |
||||||
Private placement issuance expense |
890 |
- |
7,530 |
- |
||||||
Equity loss on investment in associate |
- |
166 |
- |
381 |
||||||
Loss on debt restructuring |
- |
- |
- |
8,065 |
||||||
(Gain)/Loss on disposal of assets |
(20) |
710 |
30 |
656 |
||||||
Other (income) expense |
7 |
1 |
(124) |
7 |
||||||
Total other expense (income) |
(6,534) |
5,442 |
17,076 |
22,237 |
||||||
Income (Loss) before income taxes |
8,800 |
(7,373) |
(17,854) |
(20,950) |
||||||
Income taxes |
1,437 |
1,281 |
4,868 |
7,422 |
||||||
Net income (loss) |
7,363 |
(8,654) |
(22,722) |
(28,372) |
||||||
(Gain)/Loss from discontinued operations |
2 |
236 |
33 |
(106) |
||||||
Net income (loss) after discontinued operations |
$ |
7,361 |
$ |
(8,890) |
$ |
(22,755) |
$ |
(28,266) |
||
Other comprehensive loss: |
||||||||||
Foreign exchange translation gain (loss) |
(22) |
4 |
(33) |
188 |
||||||
Comprehensive income (loss) |
$ |
7,339 |
$ |
(8,886) |
$ |
(22,788) |
$ |
(28,078) |
||
Net loss per share |
||||||||||
Basic |
$ |
0.03 |
$ |
(0.04) |
$ |
(0.10) |
$ |
(0.14) |
||
Diluted |
$ |
0.02 |
$ |
(0.04) |
$ |
(0.10) |
$ |
(0.14) |
|
||||
STATEMENT OF CASH FLOWS |
||||
(USD '000) |
||||
For the nine months ended |
||||
2021 |
2020 |
|||
Operating activities |
||||
Net loss |
$ |
(22,755) |
$ |
(28,266) |
Adjustments to reconcile net loss to net cash used in operating activities: |
||||
Unrealized gain on changes in fair value of biological assets |
(11,768) |
(23,945) |
||
Realized gain on changes in fair value of biological assets |
14,433 |
18,566 |
||
Share-based compensation |
3,883 |
4,938 |
||
Depreciation and amortization |
7,529 |
6,146 |
||
Discontinued operations |
33 |
(106) |
||
Accretion of convertible debentures |
3,457 |
5,974 |
||
Interest on lease liabilities |
1,911 |
3,324 |
||
Change in fair market value of derivative |
(1,551) |
1,680 |
||
Loss on investment in associate |
- |
381 |
||
Loss on debt restructuring |
- |
8,065 |
||
(Gain)/Loss on disposal of assets |
30 |
656 |
||
Deferred tax expense |
(852) |
1,700 |
||
Changes in operating assets and liabilities: |
||||
Accounts receivable |
(153) |
79 |
||
Inventory |
(4,969) |
(2,930) |
||
Biological assets |
(3,859) |
3,096 |
||
Prepaid expenses and other current assets |
1,632 |
(492) |
||
Right-of-use assets |
(2,395) |
(1,439) |
||
Right-of-use liabilties |
2,378 |
- |
||
Other assets |
(105) |
(99) |
||
Accounts payable |
(123) |
(309) |
||
Accrued liabilities |
(396) |
2,205 |
||
Income taxes |
(9,553) |
4,909 |
||
Other liabilities |
- |
(411) |
||
Net cash provided by (used in) operating activities |
(23,193) |
3,723 |
||
Investing activities |
||||
Purchases of property and equipment |
(15,210) |
(3,136) |
||
Purchase of intangile assets |
(318) |
- |
||
Payment of notes receivable |
1,477 |
350 |
||
Proceeds from sale of property and equipment |
29 |
- |
||
Notes receivable |
(1,802) |
(1,375) |
||
Proceeds from sale of subsidiary |
- |
600 |
||
Net cash used in investing activities |
(15,824) |
(3,561) |
||
Financing activities |
||||
Proceeds from issuance of shares and warrants |
23,730 |
4,351 |
||
Proceeds from issuance of debt, net of loan issuance costs |
63,086 |
62 |
||
Payment of lease obligations |
(3,342) |
(3,207) |
||
Exercise of warrants |
1,365 |
- |
||
Principal repayments of notes payable |
(35,373) |
- |
||
Net cash provided by financing activities |
49,466 |
1,206 |
||
Effect of foreign exchange on cash and cash equivalents |
(33) |
188 |
||
Net increase (decrease) in cash and cash equivalents |
10,416 |
1,556 |
||
Cash and cash equivalents, beginning of period |
3,392 |
2,516 |
||
Cash and cash equivalents, end of period |
$ |
13,808 |
$ |
4,072 |
|
||||||
ADJUSTED EBITDA RECONCILIATION |
||||||
(USD '000) |
||||||
Three months ended |
||||||
|
|
Variance |
||||
Net income (loss) |
$ |
7,361 |
$ |
(8,890) |
$ |
16,251 |
Interest expense |
3,383 |
3,892 |
(509) |
|||
Income taxes |
1,437 |
1,281 |
156 |
|||
Depreciation and amortization |
2,844 |
2,100 |
744 |
|||
EBITDA |
$ |
15,025 |
$ |
(1,617) |
$ |
16,642 |
Three months ended |
||||||
|
|
Variance |
||||
EBITDA |
$ |
15,025 |
$ |
(1,617) |
$ |
16,642 |
Change in fair value of biological assets |
(1,000) |
1,788 |
(2,788) |
|||
Change in fair market value of derivative |
- |
673 |
(673) |
|||
Loss on debt settlement |
(10,794) |
- |
(10,794) |
|||
Private placement issuance expense |
890 |
- |
890 |
|||
Share-based compensation |
731 |
1,689 |
(958) |
|||
Discontinued operations |
2 |
236 |
(234) |
|||
(Gain)/Loss on disposal of assets |
(20) |
$ |
710 |
(730) |
||
Other non-recurring expense/(income) |
52 |
166 |
(114) |
|||
Adjusted EBITDA |
$ |
4,886 |
$ |
3,645 |
$ |
1,241 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/cansortium-reports-third-quarter-2021-financial-results-301434405.html
SOURCE